ZA200901874B - Stat3/5 activation inhibitor - Google Patents
Stat3/5 activation inhibitorInfo
- Publication number
- ZA200901874B ZA200901874B ZA200901874A ZA200901874A ZA200901874B ZA 200901874 B ZA200901874 B ZA 200901874B ZA 200901874 A ZA200901874 A ZA 200901874A ZA 200901874 A ZA200901874 A ZA 200901874A ZA 200901874 B ZA200901874 B ZA 200901874B
- Authority
- ZA
- South Africa
- Prior art keywords
- stat3
- activation inhibitor
- inhibitor
- activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006271172 | 2006-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200901874B true ZA200901874B (en) | 2010-07-28 |
Family
ID=38896700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200901874A ZA200901874B (en) | 2006-10-02 | 2007-10-02 | Stat3/5 activation inhibitor |
Country Status (20)
Country | Link |
---|---|
US (2) | US8263599B2 (ja) |
EP (2) | EP2089373A1 (ja) |
JP (1) | JP5068821B2 (ja) |
KR (1) | KR101148805B1 (ja) |
CN (1) | CN101522657B (ja) |
AR (1) | AR063073A1 (ja) |
AU (1) | AU2007305511A1 (ja) |
BR (1) | BRPI0717218A2 (ja) |
CA (1) | CA2665000C (ja) |
HK (1) | HK1131619A1 (ja) |
IL (1) | IL197723A (ja) |
MX (1) | MX2009003256A (ja) |
MY (1) | MY150229A (ja) |
NO (1) | NO20090856L (ja) |
NZ (1) | NZ598061A (ja) |
RU (1) | RU2489148C2 (ja) |
TW (1) | TWI336699B (ja) |
UA (1) | UA95978C2 (ja) |
WO (1) | WO2008044667A1 (ja) |
ZA (1) | ZA200901874B (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0514150A (pt) | 2004-08-06 | 2007-11-27 | Otsuka Pharma Co Ltd | composto aromático ou um sal do mesmo, método para produzir o mesmo, e, composição farmacêutica para tratar a fibrose |
DE602006016313D1 (de) | 2005-09-16 | 2010-09-30 | Arrow Therapeutics Ltd | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c |
US8236826B2 (en) * | 2005-12-05 | 2012-08-07 | Otsuka Pharmaceutical Co., Ltd. | Diarylether derivatives as antitumor agents |
US8466290B2 (en) | 2008-07-10 | 2013-06-18 | Pharma Ip General Incorporated Association | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
JP5688918B2 (ja) * | 2009-04-28 | 2015-03-25 | 大塚製薬株式会社 | 医薬組成物 |
PL2520575T3 (pl) * | 2009-12-28 | 2017-05-31 | General Incorporated Association Pharma Valley Project Supporting Organization | Związek 1,3,4-oksadiazolo-2-karboksyamidowy |
AR080057A1 (es) | 2010-01-29 | 2012-03-07 | Otsuka Pharma Co Ltd | Piridinas disustituidas como anticancerigenos |
SI2624833T1 (sl) * | 2010-10-04 | 2015-03-31 | Otsuka Pharmaceutical Co., Ltd. | Derivati 4-(metilaminofenoksi)piridin-3-il-benzamida za zdravljenje raka |
CN102921007B (zh) * | 2011-08-09 | 2014-12-10 | 中国科学院上海生命科学研究院 | 防治胰岛素抵抗和糖尿病的方法和试剂 |
TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
US9650399B2 (en) * | 2012-05-25 | 2017-05-16 | The Governing Council Of The University Of Toronto | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
CN103880707B (zh) * | 2012-12-19 | 2016-04-13 | 上海交通大学医学院 | Stat3小分子抑制剂及其应用 |
JP2016523963A (ja) * | 2013-07-08 | 2016-08-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | アリールアミドキナーゼ阻害剤 |
US10045979B2 (en) * | 2014-05-19 | 2018-08-14 | Merial Inc. | Anthelmintic compounds |
CA2950612C (en) | 2014-05-30 | 2023-05-23 | The Governing Council Of The University Of Toronto | Sulfonamide compounds and their use as stat5 inhibitors |
KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
CN110573151A (zh) | 2017-04-26 | 2019-12-13 | 辛辛那提大学 | 用于治疗急性髓性白血病的方法、试剂和组合物 |
TWI650120B (zh) * | 2017-07-21 | 2019-02-11 | 寶騰生醫股份有限公司 | 一種醫藥組成物用於製備治療或預防個體感染病毒之藥物的用途 |
US10882821B1 (en) | 2017-09-26 | 2021-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
CN112203501A (zh) | 2018-06-01 | 2021-01-08 | 日洋服务株式会社 | 植物的栽培方法和植物的栽培装置 |
CN111763217B (zh) * | 2019-03-30 | 2022-06-28 | 上海凌达生物医药有限公司 | 一类噻吩并氮杂环类化合物、制备方法和用途 |
MA55565A (fr) | 2019-04-05 | 2022-02-09 | Kymera Therapeutics Inc | Agents de dégradation de stat et leurs utilisations |
JP7268164B2 (ja) | 2019-08-06 | 2023-05-02 | 正月 白川 | 植物の栽培方法及び植物の栽培装置 |
RU2742188C1 (ru) * | 2020-07-22 | 2021-02-03 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. | Способ лечения оптической нейропатии у больных с отечным экзофтальмом |
CN117362206B (zh) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | 一类芳基磺酰胺类化合物、合成方法及用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE629102A (ja) * | 1961-03-29 | |||
NL7111711A (ja) | 1970-09-17 | 1972-03-21 | ||
US3715375A (en) * | 1970-09-17 | 1973-02-06 | Merck & Co Inc | New diphenyl sulfones |
GB1494117A (en) | 1974-11-02 | 1977-12-07 | Bayer Ag | Process for the preparation of acid amides |
DE2707659A1 (de) * | 1977-02-23 | 1978-08-24 | Bayer Ag | Selbstvernetzbare polyurethane |
DE2707660C2 (de) * | 1977-02-23 | 1985-12-19 | Bayer Ag, 5090 Leverkusen | Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung |
DE2812252A1 (de) * | 1978-03-21 | 1979-10-04 | Bayer Ag | 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel |
US4978672A (en) | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
EP0500495A3 (en) * | 1991-02-21 | 1993-04-07 | Ciba-Geigy Ag | Thermosetting composition |
DE69314718T2 (de) | 1992-07-21 | 1998-02-26 | Ciba Geigy Ag | Oxamidsäure-Derivate als hypocholesterämische Mittel |
AU7006094A (en) | 1993-06-30 | 1995-01-24 | Wellcome Foundation Limited, The | Anti-atherosclerotic diaryl compounds |
EP0832060A1 (en) | 1995-06-07 | 1998-04-01 | The Institute Of Materia Medica Of Chinese Academy Of Medical Sciences | Chalcone retinoids and methods of use of same |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
EP1060171A2 (de) | 1998-02-06 | 2000-12-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase-inhibitoren |
US6489327B1 (en) | 1998-02-06 | 2002-12-03 | Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. | Tryptase inhibitors |
AR015733A1 (es) | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
TWI245035B (en) | 1998-06-26 | 2005-12-11 | Ono Pharmaceutical Co | Amino acid derivatives and a pharmaceutical composition comprising the derivatives |
DE69920923T2 (de) | 1998-07-24 | 2005-10-20 | Teijin Ltd. | Anthranilsäurederivate |
US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
CA2362401A1 (en) | 1999-02-04 | 2000-08-10 | Paul Fleming | G-protein coupled heptahelical receptor binding compounds and methods of use thereof |
CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
AU5570600A (en) | 1999-07-01 | 2001-01-22 | Ajinomoto Co., Inc. | Heterocyclic compounds and medicinal use thereof |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
JP2001089450A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ピリジン誘導体含有医薬製剤 |
WO2001060354A1 (fr) | 2000-02-15 | 2001-08-23 | Teijin Limited | Medicament anticancereux comprenant un derive d'acide anthranilique en tant qu'ingredient actif |
AU5741301A (en) | 2000-05-22 | 2001-12-03 | Aventis Pharm Prod Inc | Arylmethylamine derivatives for use as tryptase inhibitors |
GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
AU2001282874A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
AU2001295850A1 (en) | 2000-09-28 | 2002-04-08 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
AU2002223626A1 (en) | 2000-10-20 | 2002-04-29 | Novartis Ag | Combinations of a thyromimetic compound and a statin |
EP1211235A3 (en) | 2000-11-30 | 2004-01-02 | JFE Chemical Corporation | Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof |
JP2004269356A (ja) | 2000-12-27 | 2004-09-30 | Ajinomoto Co Inc | 創傷部癒着防止剤 |
GB2374009A (en) | 2001-02-12 | 2002-10-09 | Novartis Ag | Method of treating hair loss |
CN1529699A (zh) | 2001-06-20 | 2004-09-15 | �Ʒ� | 新的磺酸衍生物 |
CA2455773A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
JP2005507923A (ja) | 2001-10-22 | 2005-03-24 | ファイザー・プロダクツ・インク | Ccr1受容体アンタゴニスト活性を有するピペラジン誘導体 |
WO2003035602A1 (fr) | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Modulateurs lipidiques |
MXPA04007936A (es) | 2002-02-15 | 2004-11-26 | Upjohn Co | Compuestos de aril-sustituidos para el tratamiento de enfermedades. |
FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
JP2004035475A (ja) | 2002-07-03 | 2004-02-05 | Ajinomoto Co Inc | TGFβ作用抑制剤 |
MXPA05009771A (es) | 2003-03-14 | 2005-10-26 | Ono Pharmaceutical Co | Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo. |
EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
KR101128275B1 (ko) | 2003-07-24 | 2012-04-12 | 레오 파마 에이/에스 | 신규한 아미노벤조페논 화합물 |
BRPI0514150A (pt) | 2004-08-06 | 2007-11-27 | Otsuka Pharma Co Ltd | composto aromático ou um sal do mesmo, método para produzir o mesmo, e, composição farmacêutica para tratar a fibrose |
US8236826B2 (en) * | 2005-12-05 | 2012-08-07 | Otsuka Pharmaceutical Co., Ltd. | Diarylether derivatives as antitumor agents |
TWI440638B (zh) * | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2007
- 2007-02-10 UA UAA200904059A patent/UA95978C2/ru unknown
- 2007-10-01 AR ARP070104333A patent/AR063073A1/es unknown
- 2007-10-02 NZ NZ598061A patent/NZ598061A/xx not_active IP Right Cessation
- 2007-10-02 US US12/311,500 patent/US8263599B2/en not_active Expired - Fee Related
- 2007-10-02 MY MYPI20091324A patent/MY150229A/en unknown
- 2007-10-02 AU AU2007305511A patent/AU2007305511A1/en not_active Abandoned
- 2007-10-02 RU RU2009116653/15A patent/RU2489148C2/ru not_active IP Right Cessation
- 2007-10-02 JP JP2009529959A patent/JP5068821B2/ja not_active Expired - Fee Related
- 2007-10-02 TW TW096136957A patent/TWI336699B/zh not_active IP Right Cessation
- 2007-10-02 EP EP07829383A patent/EP2089373A1/en not_active Withdrawn
- 2007-10-02 CA CA2665000A patent/CA2665000C/en not_active Expired - Fee Related
- 2007-10-02 BR BRPI0717218-4A2A patent/BRPI0717218A2/pt not_active IP Right Cessation
- 2007-10-02 MX MX2009003256A patent/MX2009003256A/es active IP Right Grant
- 2007-10-02 EP EP13153028.9A patent/EP2612858A1/en not_active Withdrawn
- 2007-10-02 CN CN200780036608.8A patent/CN101522657B/zh not_active Expired - Fee Related
- 2007-10-02 WO PCT/JP2007/069645 patent/WO2008044667A1/en active Application Filing
- 2007-10-02 KR KR1020097006358A patent/KR101148805B1/ko not_active IP Right Cessation
- 2007-10-02 ZA ZA200901874A patent/ZA200901874B/xx unknown
-
2009
- 2009-02-25 NO NO20090856A patent/NO20090856L/no not_active Application Discontinuation
- 2009-03-19 IL IL197723A patent/IL197723A/en not_active IP Right Cessation
- 2009-12-03 HK HK09111385.1A patent/HK1131619A1/xx not_active IP Right Cessation
-
2012
- 2012-06-18 US US13/526,283 patent/US20120322807A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2089373A1 (en) | 2009-08-19 |
HK1131619A1 (en) | 2010-01-29 |
US20120322807A1 (en) | 2012-12-20 |
AU2007305511A1 (en) | 2008-04-17 |
TW200823189A (en) | 2008-06-01 |
BRPI0717218A2 (pt) | 2013-09-24 |
WO2008044667A1 (en) | 2008-04-17 |
NZ598061A (en) | 2013-05-31 |
CN101522657A (zh) | 2009-09-02 |
CA2665000A1 (en) | 2008-04-17 |
CN101522657B (zh) | 2014-10-15 |
AR063073A1 (es) | 2008-12-23 |
KR20090043008A (ko) | 2009-05-04 |
KR101148805B1 (ko) | 2012-07-10 |
JP2010505762A (ja) | 2010-02-25 |
MX2009003256A (es) | 2009-04-08 |
US8263599B2 (en) | 2012-09-11 |
RU2489148C2 (ru) | 2013-08-10 |
EP2612858A1 (en) | 2013-07-10 |
RU2009116653A (ru) | 2010-11-10 |
TWI336699B (en) | 2011-02-01 |
NO20090856L (no) | 2009-03-27 |
UA95978C2 (ru) | 2011-09-26 |
JP5068821B2 (ja) | 2012-11-07 |
IL197723A (en) | 2015-02-26 |
IL197723A0 (en) | 2009-12-24 |
US20100210661A1 (en) | 2010-08-19 |
MY150229A (en) | 2013-12-31 |
CA2665000C (en) | 2015-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200901874B (en) | Stat3/5 activation inhibitor | |
EP1963462A4 (en) | CORROSION INHIBITOR | |
GB0516967D0 (en) | Inhibitors | |
GB0606655D0 (en) | Showerpod 1 | |
GB0520876D0 (en) | Corrosion inhibitor | |
GB0624628D0 (en) | Duty 3 | |
GB0506443D0 (en) | Novel inhibitors | |
GB0604634D0 (en) | Corcost 15 | |
GB0604493D0 (en) | Corcost 4 | |
GB0615058D0 (en) | Corcost 406 | |
GB0615057D0 (en) | Corcost 306 | |
GB0615056D0 (en) | Corcost 106 | |
GB0615051D0 (en) | Corcost 1306 | |
GB0615050D0 (en) | Corcost 706 | |
GB0612310D0 (en) | Corcost 1506 | |
GB0612239D0 (en) | Corcost 106 | |
GB0612198D0 (en) | Corcost 406 | |
GB0610406D0 (en) | MoveClick 18 | |
GB0604926D0 (en) | MoveClick 15 | |
GB0604639D0 (en) | Corcost 13 | |
GB0604638D0 (en) | Corcost 11 | |
GB0604637D0 (en) | Corcost 10 | |
GB0604636D0 (en) | Corcost 9 | |
GB0615330D0 (en) | Corcost 2006 | |
GB0604633D0 (en) | Corcost 12 |